Newly launched Judo Bio aims to develop ligand-siRNA conjugates through its Selectively Targeting RNA Into KidnEy (STRIKE) ...
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) and Moderna, Inc. (NASDAQ:MRNA) have reached a stipulation in their ongoing ...
Zacks.com on MSN5d
Here's Why You Should Add ALNY Stock to Your Portfolio Right NowAlnylam Pharmaceuticals ALNY focuses on developing novel therapeutics based on RNAi technology. The company’s pipeline of ...
With the business potentially at an important milestone, we thought we'd take a closer look at Alnylam Pharmaceuticals, ...
Camp4 Therapeutics Inc., a Cambridge biotech that has already struck deals with Biogen Inc. and Alnylam Pharmaceuticals Inc., ...
Buying $100 In ALNY: If an investor had bought $100 of ALNY stock 15 years ago, it would be worth $1,295.68 today based on a ...
Two new analyses from HELIOS-B answer important questions, but some uncertainties remain, says Julie Rosenthal.
Michael Ulz, an analyst from Morgan Stanley, maintained the Hold rating on Alnylam Pharma (ALNY – Research Report). The associated price ...
US RNAi therapeutics company Alnylam Pharmaceuticals has released two new data sets from the HELIOS-B Phase III study of ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will webcast its upcoming TTR Investor Day event on ...
Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback